Prudential PLC Hutchmed (China) LTD Transaction History

Prudential PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$17.17 - $25.95 $72.4 Million - $109 Million	-4,215,866 Closed	0 $0
Q3 2019 Nov 13, 2019	SELL	$17.84 - $22.69 $7.36 Million - $9.36 Million	-412,381 Reduced 8.91%	4,215,866 $75.9 Million
Q2 2019 Aug 14, 2019	BUY	$22.0 - $31.78 $5.59 Million - $8.08 Million	254,151 Added 5.81%	4,628,247 $102 Million
Q1 2019 May 13, 2019	BUY	$21.27 - $30.58 $5.57 Million - $8 Million	261,684 Added 6.36%	4,374,096 $134 Million
Q4 2018 Feb 13, 2019	SELL	$23.09 - $37.69 $3.12 Million - $5.1 Million	-135,336 Reduced 3.19%	4,112,412 $95 Million
Q3 2018 Nov 14, 2018	BUY	$26.55 - $34.38 $3.6 Million - $4.66 Million	135,652 Added 3.3%	4,247,748 $137 Million
Q2 2018 Aug 14, 2018	BUY	$27.79 - $34.49 $5.96 Million - $7.4 Million	214,640 Added 5.51%	4,112,096 $124 Million
Q1 2018 May 15, 2018	BUY	$28.87 - $41.13 $49.3 Million - $70.2 Million	1,706,618 Added 77.9%	3,897,456 $115 Million
Q3 2017 Nov 14, 2017	SELL	$22.15 - $27.5 $886,000 - $1.1 Million	-40,000 Reduced 1.79%	2,190,838 $59.7 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,230,838	2,230,838 $52 Million

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.19B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Prudential PLC, based on Form 13F filings with the SEC.

Stay updated on Prudential PLC with notifications on news.